Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

326.29 +3.00 (+0.93%)
Streaming Delayed Price Updated: 12:36 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,442
Open 323.99
Bid (Size) 325.63 (100)
Ask (Size) 329.68 (100)
Prev. Close 323.29
Today's Range 317.82 - 330.44
52wk Range 26.70 - 328.60
Shares Outstanding 44,712,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire

Performance

YTD
+13.9%
+13.9%
1 Month
+18.3%
+18.3%
3 Month
+77.7%
+77.7%
6 Month
+565.2%
+565.2%
1 Year
+287.3%
+287.3%

More News

Read More
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Why Praxis Precision Medicines Stock Popped Today ↗
Via The Motley Fool
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗
Via Stocktwits
News headline image
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗
Via Stocktwits
News headline image
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On? ↗
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?
Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.
What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?
Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?
The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market
What is the current price of Praxis Precision Medicines, Inc. - Common Stock?
The current price of Praxis Precision Medicines, Inc. - Common Stock is 326.29
When was Praxis Precision Medicines, Inc. - Common Stock last traded?
The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 02/12/26 12:36 PM ET
What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?
The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 14.59B
How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?
Praxis Precision Medicines, Inc. - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.